Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians--including, but not limited to, office managers, billing specialists, receptionists, and administrative staff--may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.


Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Sheraton Lisle Naperville
3000 Warrenville Road
Lisle, IL 60532


To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!


Click on the day of the conference to see course descriptions, UAN numbers, and AANP pharmacology credits.

Saturday, June 2, 2018

Schedule (subject to change)

7:00a - 7:30a - Registration and Exhibits
Coffee will be served. 

7:30a - 8:30a - Pain Pathophysiology Unraveled

UAN 0530-0000-18-047-L01-P

AANP Rx Hours 0.0

Course Description

In order to successfully clinically manage pain, it is essential to begin with an understanding of the underlying mechanisms responsible for its generation. A skillful approach based upon better knowledge concerning the anatomical structures, pathways, and events that result in pain is more likely to lead to effective clinical management of pain. The discussion will include an overview of medication classes typically considered for pain and the pathways they affect.

David M. Glick, DC, DAAPM, CPE, FASPE

8:30a - 9:30a - Product, Disease Awareness, Medical Information Program*
Breakfast will be served.
Sponsored by Arbor Pharmaceuticals, Narayan Tata, MD

9:30a - 9:40a - Break & Exhibits

9:40a - 10:40a - What's All the "GABA" About? Pregabalin and Gabapentin Abuse

UAN 0530-0000-18-058-L01-P

AANP Rx Hours 0.0

Course Description

The gabapentinoids are a popular class of medications among prescribers for use in chronic pain and various other neurological conditions. In fact, prescription rates for both gabapentin and pregabalin have increased in the United States and other countries in recent years. However, these medications have a street value to a newer niche of users, including patients taking them at megadoses to enhance the effects of other psychotropic drugs, and other patients taking them to manage or mitigate opioid withdrawal symptoms and possibly even opioid cravings. While pregabalin is already classified as a controlled substance, gabapentin does not yet carry this classification. In response to rising abuse, various states and regulatory bodies are considering changes to enhance patient safety and protect the provider's license. Learn what changes you should make to your practice, if any, in light of the growing abuse of gabapentinoids and how to identify patients potentially abusing them.

Courtney M. Kominek, PharmD, BCPS, CPE

10:40a - 11:40a - Reefer Madness: Taking the Insanity Out of Medical Cannabinoids

UAN 0530-0000-18-049-L01-P

AANP Rx Hours 0.0

Course Description

Medical, and recreational, marijuana serve as sources of great confusion to patients and clinicians alike. A culture of "neuromysticism" around medical marijuana has arisen, leaving patients and clinicians alike confused regarding what constitutes "medical" marijuana. A part of this confusion is related to the poor quality of the available research on safety and efficacy, which are due, in part, to the restrictive scheduling of the drug. This lecture will focus on what we know, and what we don't know, about the efficacy and safety of medical cannabinoids. Specific recommendations regarding the safest and most effective use of medical marijuana as part of a pain management armamentarium will be provided.

Michael E. Schatman, PhD, CPE, DASPE

11:40a - 12:00p - Faculty Q&A

12:00p - 12:10p - Break & Exhibits

12:10p - 1:10p - Product, Disease Awareness, Medical Information Program*
Lunch will be served.
Sponsored by Salix Pharmaceuticals, Gerald Sacks, MD

1:10p - 4:20p - Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)

3.0 AMA PRA Category 1TM Credits [Compliant with the FDA ER/LA Opioid REMS education requirements]

UAN 0530-9999-18-064-L01-P

AANP Rx Hours 0.5

Program Overview: Pain is a significant public health problem, affecting more than 100 million adults in the US and causing significant reductions in patients' quality of life. The use of narcotic medications for pain management has increased dramatically in the US over the past two decades. However, pain patients are often undertreated due to a variety of physician- and patient-related concerns and barriers.

In addition, despite the pain-relieving properties of opioid medications, the potential for abuse remains a concern. In response to this apprehension about opioid misuse, overdose, abuse, and addiction, the Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risks for long-acting and extended-release opioid analgesics.

The activity, Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS), incorporates the REMS blueprint into education that is designed to induce changes in physician knowledge, competence, and performance that will translate into improved quality of patient care and reduced pain for patients.

Target Audience: This education is intended for primary care providers and other clinicians involved in pain management, and is designed to help them recognize and balance optimal pain reduction to improve function and productivity with minimization of adverse events (e.g. abuse, addiction, and risk of workplace accidents). Additional challenges to optimal pain management include keeping up to date with the increasing volume of information on pain management, implementing changes recommended by evolving guidelines, and recognizing changes to practice needed to combat the growing rate of opioid abuse.

Jointly provided by Global Education Group and Rockpointe

This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.

Lynn Webster, MD
Jeff Fudin, PharmD


*Not certified for credit.